Macitentan in pulmonary arterial hypertension: The SERAPHIN trial

Major limitations of pulmonary arterial hypertension (PAH) drug trials include the small number of enrolled patients, short term follow up (12-16 weeks), and lack of morbidity and mortality primary endpoints. The recently published SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary...

Descripción completa

Detalles Bibliográficos
Autor principal: Said, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bloomsbury Qatar Foundation Journals 2014
Materias:
Lessons from the Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220429/
https://www.ncbi.nlm.nih.gov/pubmed/25405173
http://dx.doi.org/10.5339/gcsp.2014.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220429/
https://www.ncbi.nlm.nih.gov/pubmed/25405173
http://dx.doi.org/10.5339/gcsp.2014.20

Ejemplares similares